Objective To evaluate the effect of inducing differenation of all trans retinoic acid (ATRA) on immunologic function of patients with gastric cancer. Methods T-lymphocyte subsets(T-Ls) and interleukin-2 receptor(sIL-2R) of 56 patients with gastric cancer after treatment of ATRA were studied. Results In radical gastric cancer resection group, the serum CD3,CD4 and CD4/CD8 rate were higher and sIL-2R were lower than those in the control group, after treatment of ATRA, CD3,CD4 and CD4/CD8 rate and sIL2R were as high as those in the control group. In the non-operative or palliative gastric resection group, CD3,CD4 and CD4/CD8 rates were increased markedly and the serum sIL-2R was decreased significantly than those in the control group. Conclusion ATRA inducing differenation can improve the immunity of the patients with gastric cancer.
The effects of all-trans retinoic acid (ATRA) on primary gastric carcinoma models made by subcutaneous implanting gastric cancer to mice were observed. Thirty-two cancer bearing nude mice were randomly divided into 4 groups: control group (group Ⅰ)， ATRA low dose feeding group (100μg/day， group Ⅱ), moderate dose feeding group (300μg/day， group Ⅲ), and high dose feeding group (1 000 μg/day, group Ⅳ). The alteration of tumor growth, morphology, cytobiology, and immuno-histochemical assay were perfermed. The results showed significant inhibition of tumor growth and inducing differentiation in the group Ⅲ and group Ⅳ as compared with group Ⅰ (Ｐ＜0.01),and inhibited expression of p53, p21 protein in implanted tumor. The authors consider that ATRA has some effects of growth inhibition and differentiation on gastric cancer cells in vivo, and these is related to the inhibition of expression p53 and p21 onco-gene of cancer cells and accelerate apoptosis of carcinoma cells.
Objective To observe the efficacy of all trans retinoic acid (ATRA) combined with 5-Fu on treating subcutaneously implanted gastric carcinoma SGC 7901 in the nude mice. Methods Thirty-two nude mice bearing tumor were randomly divided into 4 groups: control group (group A), ATRA 1 000 μg/d orally taken group (group B), 5-Fu 27 mg/kg group peritoneally injected (group C), 5-Fu 13.5 mg/kg combined with ATRA 500 μg/d group (group D). Results Significant inhibition of tumor growth was shown in the group B, group C and group D as compared with group A (Ｐ＜0.01), with the tumor growth inhibition rate and the tumor weight inhibition rate at the 7 weeks after the treatment being 56.88%, 49.00%, 70.00% and 56.10%, 51.64%, 76.95%. Conclusion ATRA combined with 5-Fu can enhance the effects of 5-Fu in treating gastric carcinoma.